Skip to main content
Top
Published in: Supportive Care in Cancer 6/2016

01-06-2016 | Original Article

Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?

Authors: Melanie A. Price, Phyllis N. Butow, Melanie L. Bell, Anna deFazio, Michael Friedlander, Joanna E. Fardell, Melinda M. Protani, Penelope M. Webb, AOCS—Quality of Life Study Investigators on behalf of the Australian Ovarian Cancer Study Group

Published in: Supportive Care in Cancer | Issue 6/2016

Login to get access

Abstract

Purpose

Women with advanced ovarian cancer generally have a poor prognosis but there is significant variability in survival despite similar disease characteristics and treatment regimens. The aim of this study was to determine whether psychosocial factors predict survival in women with ovarian cancer, controlling for potential confounders.

Methods

The sample comprised 798 women with invasive ovarian cancer recruited into the Australian Ovarian Cancer Study and a subsequent quality of life study. Validated measures of depression, optimism, minimization, helplessness/hopelessness, and social support were completed 3–6 monthly for up to 2 years. Four hundred nineteen women (52.5 %) died over the follow-up period. Associations between time-varying psychosocial variables and survival were tested using adjusted Cox proportional hazard models.

Results

There was a significant interaction of psychosocial variables measured prior to first progression and overall survival, with higher optimism (adjusted hazard ratio per 1 standard deviation (HR) = 0.80, 95 % confidence interval (CI) 0.65–0.97), higher minimization (HR = 0.79, CI 0.66–0.94), and lower helplessness/hopelessness (HR = 1.40, CI 1.15–1.71) associated with longer survival. After disease progression, these variables were not associated with survival (optimism HR = 1.10, CI 0.95–1.27; minimization HR = 1.12, CI 0.95–1.31; and helplessness/hopelessness HR = 0.86, CI 0.74–1.00). Depression and social support were not associated with survival.

Conclusions

In women with invasive ovarian cancer, psychosocial variables prior to disease progression appear to impact on overall survival, suggesting a preventive rather than modifying role. Addressing psychosocial responses to cancer and their potential impact on treatment decision-making early in the disease trajectory may benefit survival and quality of life.
Literature
1.
go back to reference Australian Institute of Health and Welfare & National Breast and Ovarian Cancer Centre. Ovarian Cancer in Australia: an overview, 2010. Canberra. Australian Institute of Health and Welfare & National Breast and Ovarian Cancer Centre. Ovarian Cancer in Australia: an overview, 2010. Canberra.
2.
3.
go back to reference Parker PA, Baile WF, deMoor C, Cohen L (2003) Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psycho-Oncology 12(2):183–193CrossRefPubMed Parker PA, Baile WF, deMoor C, Cohen L (2003) Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psycho-Oncology 12(2):183–193CrossRefPubMed
4.
go back to reference Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR (2013) A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU International. 112(2):E67–E75. doi:10.1111/bju.12209 CrossRefPubMed Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR (2013) A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU International. 112(2):E67–E75. doi:10.​1111/​bju.​12209 CrossRefPubMed
10.
go back to reference Antoni MH. Psychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer. Brain Behav Immun. 2013; 30(SI):S88-S98. doi:10.1016/j.bbi. 2012.05.009 Antoni MH. Psychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer. Brain Behav Immun. 2013; 30(SI):S88-S98. doi:10.1016/j.bbi. 2012.05.009
14.
go back to reference Butow PN, Brown JE, Coates AS, Dunn SM (2001) Psychosocial predictors of outcome IV: patients with early-stage breast cancer. Breast 10(Suppl 3):182–189CrossRef Butow PN, Brown JE, Coates AS, Dunn SM (2001) Psychosocial predictors of outcome IV: patients with early-stage breast cancer. Breast 10(Suppl 3):182–189CrossRef
17.
go back to reference Chida Y, Hamer M, Wardle J, Steptoe A (2008) Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Rev Clin Oncol 5:466–475. doi:10.1038/ncponc1134 CrossRef Chida Y, Hamer M, Wardle J, Steptoe A (2008) Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Rev Clin Oncol 5:466–475. doi:10.​1038/​ncponc1134 CrossRef
22.
go back to reference Spiegel D, Butler LD, Giese-Davis J, et al. (2007) Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Cancer 110(5):1130–1138. doi:10.1002/cncr.22890 CrossRefPubMed Spiegel D, Butler LD, Giese-Davis J, et al. (2007) Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. Cancer 110(5):1130–1138. doi:10.​1002/​cncr.​22890 CrossRefPubMed
23.
24.
go back to reference Kissane D (2009) Beyond the psychotherapy and survival debate: the challenge of social disparity, depression and treatment adherence in psychosocial cancer care. Psycho-Oncology 18(1):1–5. doi:10.1002/pon.1493 CrossRefPubMed Kissane D (2009) Beyond the psychotherapy and survival debate: the challenge of social disparity, depression and treatment adherence in psychosocial cancer care. Psycho-Oncology 18(1):1–5. doi:10.​1002/​pon.​1493 CrossRefPubMed
27.
go back to reference Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM (2005) Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 104(2):305–313. doi:10.1002/cncr.21147 CrossRefPubMed Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM (2005) Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 104(2):305–313. doi:10.​1002/​cncr.​21147 CrossRefPubMed
28.
go back to reference Jordan SJ, Green AC, Whiteman DC, et al. (2008) Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer 122:1598–1603. doi:10.1002/ijc.23287 CrossRefPubMed Jordan SJ, Green AC, Whiteman DC, et al. (2008) Serous ovarian, fallopian tube and primary peritoneal cancers: a comparative epidemiological analysis. Int J Cancer 122:1598–1603. doi:10.​1002/​ijc.​23287 CrossRefPubMed
30.
go back to reference Price MA, Butow PN, Costa DS, et al. (2010) Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their carers. Med J Aust 193(5 Suppl):S52–S57PubMed Price MA, Butow PN, Costa DS, et al. (2010) Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their carers. Med J Aust 193(5 Suppl):S52–S57PubMed
31.
go back to reference Rustin GJS, Vergote I, Eisenhauer E, et al. (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21(2):419–423. doi:10.1097/IGC.0b013e3182070f17 CrossRefPubMed Rustin GJS, Vergote I, Eisenhauer E, et al. (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 21(2):419–423. doi:10.​1097/​IGC.​0b013e3182070f17​ CrossRefPubMed
35.
go back to reference Scheier MF, Carver CS, Bridges MW (1994) Distinguishing optimism from neuroticism (and trait anxiety, self mastery, and self esteem): a reevaluation of the life orientation test. J Pers Soc Psychol 67(6):1063–78. doi:10.1037/0022-3514.67.6.1063 Scheier MF, Carver CS, Bridges MW (1994) Distinguishing optimism from neuroticism (and trait anxiety, self mastery, and self esteem): a reevaluation of the life orientation test. J Pers Soc Psychol 67(6):1063–78. doi:10.​1037/​0022-3514.​67.​6.​1063
36.
go back to reference Broadhead WE, Gehbach SH, de Gruy FV, Kaplan BH (1988) The Duke-UNC Functional Social Support Questionnaire. Measurement of social support in family medicine patients. Med Care 26(7):709–723CrossRefPubMed Broadhead WE, Gehbach SH, de Gruy FV, Kaplan BH (1988) The Duke-UNC Functional Social Support Questionnaire. Measurement of social support in family medicine patients. Med Care 26(7):709–723CrossRefPubMed
40.
go back to reference Australian Cancer Network and National Breast Cancer Centre. Clinical practice guidelines for the management of women with epithelial ovarian cancer. Camperdown, Sydney, Australia: National Breast Cancer Centre; 2004. Australian Cancer Network and National Breast Cancer Centre. Clinical practice guidelines for the management of women with epithelial ovarian cancer. Camperdown, Sydney, Australia: National Breast Cancer Centre; 2004.
Metadata
Title
Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?
Authors
Melanie A. Price
Phyllis N. Butow
Melanie L. Bell
Anna deFazio
Michael Friedlander
Joanna E. Fardell
Melinda M. Protani
Penelope M. Webb
AOCS—Quality of Life Study Investigators on behalf of the Australian Ovarian Cancer Study Group
Publication date
01-06-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-3070-5

Other articles of this Issue 6/2016

Supportive Care in Cancer 6/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine